Is Inhibrx Biosciences, Inc. (INBX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 15.2% / 30% | 0.0% / 30% | 5470.0% / 5% | ✗ NOT HALAL |
| DJIM | 0.8% / 33% | 15.2% / 33% | 0.0% / 33% | 5470.0% / 5% | ✗ NOT HALAL |
| MSCI | 4.5% / 33% | 84.4% / 33% | 0.2% / 33% | 5470.0% / 5% | ✗ NOT HALAL |
| S&P | 0.8% / 33% | 15.2% / 33% | 0.0% / 33% | 5470.0% / 5% | ✗ NOT HALAL |
| FTSE | 4.5% / 33% | 84.4% / 33% | 0.2% / 50% | 5470.0% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -10386.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -197.8% | |
| Return on Assets (ROA) | -51.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$194M |
| Free Cash Flow | -$197M |
| Total Debt | $8M |
| Debt-to-Equity | 1338.8 |
| Current Ratio | 3.9 |
| Total Assets | $181M |
Price & Trading
| Last Close | $65.79 |
| 50-Day MA | $74.41 |
| 200-Day MA | $52.62 |
| Avg Volume | 194K |
|
52-Week Range
$10.80
| |
About Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Inhibrx Biosciences, Inc. (INBX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Inhibrx Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Inhibrx Biosciences, Inc.'s debt ratio?
Inhibrx Biosciences, Inc.'s debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.5%.
What are Inhibrx Biosciences, Inc.'s key financial metrics?
Inhibrx Biosciences, Inc. has a market capitalization of $853M, and revenue of $200,000. Return on equity stands at -197.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.